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Mitochondrial CyP-D (cyclophilin-D) catalyses formation of
the PT (permeability transition) pore, a key lesion in the
pathogenesis of I/R (ischaemia/reperfusion) injury. There is
evidence [Malouitre, Dube, Selwood and Crompton (2010)
Biochem. J. 425, 137–148] that cytoprotection by the CyP
inhibitor CsA (cyclosporin A) is improved by selective targeting
to mitochondria. To investigate this further, we have developed
an improved mtCsA (mitochondrial-targeted CsA) by modifying
the spacer linking the CsA to the TPP
+ (triphenylphosphonium)
(mitochondrial-targeting) cation. The new mtCsA exhibits an 18-
fold increase in binding afﬁnity for CyP-D over the prototype
and a 12-fold increase in potency of inhibition of the PT in
isolatedmitochondria,owingtoamarkeddecreaseinnon-speciﬁc
binding. The cytoprotective capacity was assessed in isolated
rat cardiomyocytes subjected to transient glucose and oxygen
deprivation (pseudo-I/R). The new mtCsA was maximally
effective at lower concentrations than CsA (3–15 nM compared
with 50–100 nM) and yielded improved cytoprotection for up
to 3 h following the pseudo-ischaemic insult (near complete
compared with 40%). These data indicate the potential value
of selective CyP-D inhibition in cytoprotection.
Key words: cyclophilin D (CyP-D), cyclosporin, ischaemia,
mitochondrial targeting, reperfusion injury (RI), triphenylphos-
phonium (TPP
+).
INTRODUCTION
Myocardial ischaemia is a major cause of death and disability.
Minimizing tissue injury requires early restoration of blood ﬂow.
After prolonged ischaemia, however, still surviving cells become
adversely affected by restored blood supply and succumb on
reperfusion. RI (reperfusion injury) is a complicating factor
in clinical procedures used to remove a coronary obstruction
(angioplasty, thrombolysis and bypass surgery) and in organ
transplantation.
Considerable evidence implicates the PT (permeability
transition) pore model of necrotic cell death [1,2] in RI. The non-
selective PT pore forms in the mitochondrial inner membrane
under the synergistic inﬂuence of high Ca
2+ concentration [3],
oxidative stress [1] and depleted adenine nucleotides [2], factors
common to RI. The resulting collapse of the proton electro-
chemical gradient allows the ATP synthase to operate in reverse,
catalysing rapid ATP hydrolysis [1] and leading to irreversible
cell injury. The molecular identity of the PT pore is controversial.
Reconstitution studies indicate that the pore forms from a mal-
functioning adenine nucleotide translocase [4–6], but additional,
or alternative, transport proteins, e.g. the phosphate carrier [7],
havealsobeenconsidered.Itisgenerallyagreed,however,thatPT
pore formation is catalysed or stabilized by CyP (cyclophilin)-D,
an intra-mitochondrial peptidylprolyl cis–trans-isomerase. CyP-
D is regulated by acetylation, which potentiates its binding to
the adenine nucleotide translocase and lowers the Ca
2+ threshold
for PT pore formation [8]. The CyP inhibitor CsA (cyclosporin
A) blocks pore formation and gives partial protection in isolated
cardiomyocyte [9], perfused heart [10] and mouse [11] models of
RI. PT pore opening is promoted by CyP-D overexpression [12]
and is attenuated by CyP-D knockout [13]. Genetic ablation of
CyP-D reduces infarct size in heart [14] and other tissues (brain
[15] and kidney [16]), and is also protective in models of degen-
erative diseases, i.e. Alzheimer’s disease [17], multiple sclerosis
[18], muscular dystrophy [19] and motor neuron disease [20].
Thus the PT pore appears to be an intrinsic feature of RI
and many other diseases leading to lethal cell injury, and, in
controlling PT pore formation, CyP-D offers a potential target for
pharmacological intervention. However, CsA may exert variable
effectsoncellviabilityowingtoitsinteractionwithcytosolicCyP-
A and other non-mitochondrial CyPs. Recently, we have shown
that targeting CsA to mitochondria, thereby minimizing extra-
mitochondrialinteractions,improvescytoprotectioninanisolated
neuronal model of ‘energy failure’ [21]. In the present paper,
we report the synthesis of a modiﬁed mtCsA (mitochondrial-
targeted CsA) with a much-improved CyP-D-binding afﬁnity
over the prototype, and show that it yields better cytoprotection
than CsA in an isolated cardiomyocyte model of RI.
EXPERIMENTAL
Synthesis of cyclosporin analogues
A scheme of the syntheses is given in Figure 1. Compound 2,
SMBz-CsA {[sarcosine-3(4-methylbenzoate)]-CsA}, was used
as a key intermediate in the synthesis of the alkyl-linked
TPP
+ (triphenylphosphonium) analogue (compound 5), as
described previously [21] and in the new alkyl linked rosamine
(compound 6) and ether-linked TPP
+ (compound 9) analogues as
Abbreviations used: CsA, cyclosporin A; CyP, cyclophilin; DCM, dichloromethane; DMF, dimethylformamide; ESI, electrospray ionization; Fmoc,
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Figure 1 Chemical synthesis of the CsA analogues
The dotted circles show the position of alkylation at the (Sar-3) of cyclosporin 1 and the
appendedmethylbenzoicacidgroupinSMBz–CsA2.Forsimplicitycyclosporininthestructures
3–9 is drawn as Cs. The reagents used in each step are: (i) lithium di-isopropylamide, THF;
4-(BrCH2)PhCOOMe; (ii) LiOH, methanol; (iii) 1-Fmoc-1,6-diaminohexane, PyBOP,
triethylamine (Et3N), THF; (iv) piperidine, DMF; (v) 5-(carboxypentyl)triphenylphosphonium
bromide, PyBOP, Et3N, THF; (vi) Rosamine acid, PyBOP, Et3N, THF; and (vii) 2-[2-(Fmoc-
amino)ethoxylamine].HCl,PyBOP,Et3N,THF;and(viii)2-(carboxyethyl)triphenylphosphonium
bromide.
described below. LC (liquid chromatography)–MS was run on an
Agilent 6130 system, using a C4 reverse-phase column with the
standard programme. Solvent A was 95% water, 5% methanol
and 0.1% formic acid. Solvent B was 5% water, 95% meth-
anol and 0.1% formic acid. Elution was with a 50% solvent A
gradient to 95% solvent B over 7 min then 95% solvent B for
8m i n .
Compound 6, mtCsA2
To a solution of the amine 4 [21] (57 mg, 0.0397
mmol) in THF (tetrahydrofuran; 2.5 ml) was added rosamine
acid [22] (46 mg, 0.119 mmol), PyBOP (benzotriazol-1-yl-
tris-pyrrolidinophosphonium hexaﬂuorophosphate; 41 mg, 0.18
mmol) and triethylamine (20 mg, 0.19 mmol) under argon at
room temperature (22◦C). The reaction mixture was stirred for
24 h at room temperature. The volatiles were removed in vacuo
to leave a yellow oil. The oil was puriﬁed by ﬂash column
chromatography on silica gel eluting with 6% methanol in DCM
(dichloromethane) followed by methanol/DCM/NH3 (aq) (1:8:1,
byvol.)togivethetitlecompound(10.1 mg,0.0056mmol,14%)
as a red solid. ESI (electrospray ionization)– TOF (time-of-ﬂight)
MS in positive-ion mode: calculated m/z for C100H153N15O15 +,
1804.1671; found m/z 1804.0834; mDa −83.7; p.p.m. −46.4;
LC–MS broad peak eluting at 7 min.
Compound 7, Fmoc (ﬂuoren-9-ylmethoxycarbonyl)-protected amine
To a stirred solution of the acid 2, SMBz-CsA (100 mg,
0.07 mmol) in dry THF (6.0 ml) was added 2-[2-(Fmoc-
amino)ethoxylamine] hydrochloride (70.0 mg, 0.12 mmol),
HATU [2-(7-aza-1H-benzotriazole-1-yl-1)-1,3,3-tetramethyl-
uronium hexaﬂuorophosphate] (70.0 mg, 0.12 mmol) and
triethylamine (0.36 mmol, 0.1 ml) under nitrogen at room
temperature and the resultant mixture was stirred for 24 h. Then
DCM (15 ml) followed by saturated NH4Cl (aq) (5 ml) were
added. The mixture was extracted with DCM (2×3 ml), and dried
using anhydrous MgSO4. The volatiles were removed in vacuo
to leave a brown oil residue. Puriﬁcation by chromatography
(SiO2,5% methanol/DCM) gave the Fmoc-protected derivative
7 (100 mg, 0.61 mmol, 82%): as a white solid. ESI–TOF MS
in positive-ion mode: calculated m/z for C89H137N13O16Na+,
1668.0282; found m/z 1668.0624; mDa −34.2; p.p.m. 20.5.
Compound 8, amine
A solution of the Fmoc compound 7 (90 mg): was stirred in 20%
piperidine in DMF (dimethylformamide; 4 ml) under argon for
24 h. The volatiles were removed in vacuo to leave a yellow
oil. The oil was puriﬁed by ﬂash column chromatography on
silica gel eluting with 6% methanol in DCM followed by
methanol/DCM/NH3 (aq) (1:8:1, by vol.) to afford the amine 8
(55 mg, 0.04 mmol, 80%) as a yellow solid and was used directly
for the next step. LC–ESI MS in positive-ion mode C74H127N13O14
m/z 1424.47 (M +1), 712.24 (M +2).
Compound 9, mtCsA3
To a solution of the amine 8 (50 mg, 0.035 mmol) in
THF (1 ml) was added (2-carboxyethyl)triphenylphosphonium
bromide (30 mg, 0.07 mmol), HATU (30 mg, 0.07 mmol)
and triethylamine (0.70 mmol, 0.1 ml) under argon at room
temperature. The reaction mixture was stirred for 24 h at
roomtemperature.Thevolatileswereremovedinvacuotoleavea
yellow oil. The oil was puriﬁed by ﬂash column chromatography
on silica gel eluting with 6% methanol in DCM followed by
methanol/DCM/NH3 (aq) (1:8:1, by vol.) to afford mtCsA3
(40 mg, 0.029 mmol, 82%) as a white solid. ESI MS in positive-
ionmode:calculatedm/zforC95H145N13O15P+ 1740.0799;found
m/z 1740.0155.
Interactions of CsA analogues with CyPs and calcineurin
Recombinant rat CyP-D and CyP-A were prepared and puriﬁed
as described previously [12,21]. CyP binding of CsA analogues
was measured from the inhibition of PPIase (peptidylprolyl
cis–trans-isomerase) activity and is expressed as an inhibitor
(dissociation) constant Ki. PPIase assays were conducted at 15◦C
in 100 mM NaCl/20 mM Hepes (pH 7.5) using the chromophoric
test peptide N-succinyl-alanyl-alanyl-prolyl-4-nitroanilide [12].
Ki values were determined using the Henderson equation for a
tight binding competitive inhibitor as described previously [21].
Linear plots were each derived from >6 rate measurements
over >10-fold range of inhibitor concentrations and best ﬁtted
by linear regression (as in Figure 2A of [21]). Interaction of the
CyP–CsA analogue complexes with calcineurin was determined
from the inhibition of the phosphatase activity of calcineurin as
a s s a y e db yt h er e l e a s eo fP i from the RII phosphopeptide (Biomol
International).
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Figure 2 Preferential inhibition of intra-mitochondrial CyP-D rather than
extra-mitochondrial CyP-A by mtCsA3
(A) Isolated mitochondria were incubated with added recombinant CyP-A and the indicated
concentrations of mtCsA3. CyP-D-dependent PT pore opening was induced by Ca2+ and
monitored from the decrease in A540 due to mitochondrial swelling. (B) Continuous lines, the
rate of PT pore opening in (A) was determined from the time taken [from the vertical arrow in
(A)] to decrease absorbance by 0.24unit [horizontal arrow in (A)] and plotted as inhibition by
mtCsA3(mtCsA3,PT).Inaparallelincubation,mitochondriaweresedimentedimmediatelyafter
addition of CaCl2 and the inhibition of CyP-A by mtCsA3 was determined (mtCsA3, CyP-A).
Broken lines inhibition of the PT and CyP-A by CsA was measured as described above for
mtCsA3. Data for mtCsA3 and CsA are representative of three experiments.
PT pore opening in isolated mitochondria
Isolated rat liver mitochondria [12] (3 mg of protein) were
incubated with continuous stirring in 3 ml of 120 mM
KCl/2 mM KH2PO4/3 mM succinate/1 μM rotenone/5 μM
EGTA/recombinant CyP-A and test cyclosporins as indicated.
After 5 min, CaCl2 was added at a constant rate of 10 μM/min
to a ﬁnal concentration of 50 μM. PT pore opening was
monitored from mitochondrial swelling according to the decrease
in absorbance at 540 nm [21]. In an identical parallel incubation
mitochondria were sedimented immediately after CaCl2 addition
and the CyP-A activity in the supernatant was determined.
Cardiomyocyte culture and assays
Primary cultures of cardiomyocytes were prepared from
14-day-old Sprague–Dawley rats, seeded on to glass coverslips,
and maintained under CO2/air (1:19) as described previously
[23]. All animal experiments conformed to UK Home
Ofﬁce legislation. For glucose-free anoxia, cells were washed
twice with PBS and incubated at 25◦C under oxygen-free
nitrogen in 120 mM NaCl/4 mM KCl/24 mM Hepes (Na
+
salt, pH 7.4)/1 mM MgSO4/1 mM CaCl2/1 mM KH2PO4/4 μM
ethidium homodimer/2 μM Hoechst 33342 and cyclosporins as
indicated in a 5-well system mounted on the microscope stage.
After 4 h, 10 mM glucose, 5% (v/v) foetal bovine serum and
50 μM t-butyl hydroperoxide were added, and the cells were
reoxygenated by gassing with air. Fluorescence images
were acquired [21] after nuclear staining with Hoechst 33342
and ethidium homodimer used to quantify total and necrotic cells
respectively.StatisticalanalysesweremadeusingpairedStudent’s
t tests and are presented as means+ −S.E.M.
RESULTS AND DISCUSSION
A mitochondrial-targeted cyclosporin with improved CyP-D binding
afﬁnity
CsA (compound 1, Figure 1) is a lipophilic cyclic undecapeptide
that inhibits the PPIase activity of CyPs. CsA inhibition of the
mitochondrial isoform CyP-D prevents PT pore formation and
partially protects against RI in experimental models (as described
in the Introduction). Recently, we reported that neuroprotection
by CsA is limited by counter-protective interactions with
extra-mitochondrial CyPs and that cytoprotection is improved
when CyP-D is inhibited selectively [21]. CyP-D selectivity was
achieved with a mitochondrial-targeted CsA, here designated
mtCsA1 (compound 5, Figure 1) in which residue 3 of the
CsA ring was conjugated via a linker to the lipophilic TPP
+
cation. The positively charged mtCsA1 was accumulated
electrophoretically by mitochondria in response to the negative-
inside inner membrane potential, enabling selective inhibition
of mitochondrial CyP-D in cells. However, the high binding
afﬁnity of CyP-D for CsA was decreased substantially by the
modiﬁcations in mtCsA1, and more mtCsA1 was required for PT
pore blockade than CsA itself. The ﬁrst aim of the present study
was therefore to investigate whether the intrinsically high binding
afﬁnity of CyP-D for CsA could be retained within this basic
strategy (CsA–linker–TPP
+) of targeting CsA to mitochondria.
The synthesis of the required analogues (Figure 1) was ac-
complished by adaptation of our previously described method for
synthesisofmtCsA1[21].SMBz-CsA(compound2)wascoupled
in solution to Fmoc-monoprotected diamine using the standard
peptide coupling reagent PyBOP to afford the corresponding
Fmoc-protected amide intermediate 3. This intermediate was
deprotected by reaction with piperidine in DMF to give amine
4 and coupled in solution to rosamine acid [22] with PyBOP and
triethylamine to produce target compound 6. The ether-linked
compounds 7–9 were prepared using similar methods.
CyP-binding afﬁnities for CsA analogues were determined
fromPPIaseinhibition,andarereportedasinhibitor(dissociation)
constants in Table 1. CyP-D bound the prototype mtCsA
compound,mtCsA1,withanafﬁnity(Ki =93 nM)approximately
1/30 of that for CsA (Ki =3 nM). Some loss of binding afﬁnity in
mtCsA1 might be anticipated. The CsA ring half inserts into the
CyP active site with residues 9–11 and 1–3 interacting with
the CyP and residues 4–8 remaining exposed to the solvent [24].
Hence position 3 additions, as in mtCsA1, might sterically hinder
binding to CyP-D. Yet the additions at position-3 that form the
linker caused relatively modest decreases in binding afﬁnity (Ki
values: compound 2, 7 nM; compound 4,1 5n M ) .T h em a j o rl o s s
ofafﬁnityoccurredwithFmoc(Ki valueforcompound3,160 nM)
and TPP
+ (Ki value for mtCsA1, 93 nM). Addition of rosamine
to the linker, as an alternative (mitochondrial-targeting) lipophilic
c a t i o nt oT P P
+, also decreased binding afﬁnity considerably (Ki
valueforcompound6,mtCsA2,202 nM).Theseﬁndingsindicate
that the large loss of binding afﬁnity is not due speciﬁcally to
TPP
+, since addition of other bulky groups caused losses at least
as great, or to modiﬁcation at position 3. Rather, it seems that
these bulky groups are not effectively separated from the CsA
by the linker, possibly as a result of hydrophobic collapse in
which the linker–TPP
+ (−Fmoc, −rosamine) folds back on
itself to maximize hydrophobic interactions, thereby stabilizing
the TPP
+ (Fmoc, rosamine) in close proximity to the CsA. We
therefore investigated the use of a shortened linker containing an
ether linkage to reduce hydrophobicity.
The ether-linked derivatives are shown as compounds 7–9
(Figure 1). Remarkably, CyP-D bound the new Fmoc and TPP
+
derivatives with an afﬁnity close to that for CsA (Ki values:
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Table 1 Inhibition by CsA derivatives of CyPs, calcineurin and the PT pore
CsAderivativesarenumberedasinFigure1.Ki valuesaretheinhibitor(dissociation)constantsforinhibitionofpuriﬁedCyP-DandCyP-A;valuesinparenthesesarethelinearcorrelationcoefﬁcients
for the lines used to derive the Ki values. Inhibition of the phosphatase activity of calcineurin was determined with 720nM complexes of CyP-A and CsA derivatives (see text); values are the average
oftwomeasurementsdifferingby<6%.I50 isdeﬁnedasthetotalcyclosporinconcentration(pmol/mgofmitochondrialprotein)yielding50%inhibitionofPTporeopeninginisolatedmitochondria
incubated as in Figure 2. Data for I50 and CyP-A inhibition are means+ −S.E.M. (three mitochondrial preparations).
Ki (nM)
Compound WR CyP-D CyP-A Calcineurin inhibition (%) I50 for PT (pmol/mg of protein) CyP-A inhibition at I50 (%)
1, CsA – – 3 (0.992) 4 (0.987) 74 125+ −10 60+ −7
2, SMBz- CsA – – 7 (0.934) 8 (0.958) −3 286+ −16 –
3 (CH2)2 Fmoc 160 (0.955) – – – –
4 (CH2)2 H 15 (0.951) – – – –
5,m t C s A 1 ( C H 2)2 CO(CH2)5PPh3
+ 93 (0.993) 115 (0.975) −5 353+ −27 9+ −1
6,m t C s A 2 ( C H 2)2 Rosamine 202 (0.990) 213 (0.995) – 770+ −32 21+ −6
7 O Fmoc 6 (0.959) – – – –
9, mtCsA3 O CO(CH2)2PPh3
+ 5 (0.971) 8 (0.982) 4 29+ −31 + −1
compound 7, 6 nM; compound 9, 5 nM). Although addition of
alkyl linker and TPP
+ to compound 2 caused a 13-fold decrease
in CyP-D-binding afﬁnity, the addition of ether linker and TPP
+
caused no loss. The new mtCsA (compound 9) is designated
mtCsA3.
CsA binding to the cytosolic isoform CyP-A can also inﬂuence
cell viability (described below) and, although mtCsA compounds
are designed to minimize interactions with CyP-A by means
of accumulation out of the cytosol into mitochondria, CyP-A
data were also obtained (Table 1). CyP-A bound CsA and the
mtCsA derivatives with a similar afﬁnity as CyP-D, conforming
to the close similarity between the CsA-binding sites in the two
isoforms [24,25]. In addition, the CyP-A–CsA complex inhibits
the protein phosphatase calcineurin [26]. To compare calcineurin
inhibition by CyP-A–mtCsA complexes, the concentrations of
CsA and derivatives were chosen to give the same concentration
(720 nM) of their respective complexes with CyP-A (calculated
from Ki values), and we conﬁrmed that, when added alone, these
concentrations of CyP-A, CsA and derivatives did not inhibit
calcineurin([21],resultsnotshown).Table1showsthat,although
the CyP-A–CsA complex inhibits calcineurin phosphatase
activity, the CyP-A complexes with the mtCsA compounds
did not. The additions at position 3 of CsA in the derivatives
presumably prevent binding of the CyP–CsA (derivative)
complexes by calcineurin which is known to involve contacts
between calcineurin and positions 3–7 of the CsA ring [24,26].
Mitochondrial accumulation of mtCsA compounds
The capacity of mitochondria to accumulate mtCsA derivatives
was evaluated by comparing inhibition of the CyP-D-dependent
PT pore and inhibition of extra-mitochondrial CyP-A in a system
comprisingisolatedmitochondriaandaddedrecombinantCyP-A.
PTporeopeningwastriggeredbyadditionofCa
2+ andmonitored
from the resultant mitochondrial swelling (Figure 2A) [21].
Ca
2+ uptake is electrophoretic and, when rapid, depresses  ϕm
(inner membrane potential) [12]. As dissipation of  ϕm would
compromise electrophoretic accumulation of mtCsA compounds,
Ca
2+ was infused slowly over several minutes to limit the rate
ofCa
2+ inﬂuxandtopreventlossof ϕm arisingfromrapidCa
2+
ﬂux [21]. Extramitochondrial CyP-A activities were determined
in parallel (identical) incubations (see the Experimental section).
Representative time courses of PT pore opening, showing
mtCsA3 inhibition, are given in Figure 2(A); equivalent time
courses were obtained for all CsA compounds analysed (I50
values, Table 1). To compare inhibition by the different
compounds, rates were calculated from the time period between
ﬁrst detection of PT pore opening in the absence of inhibitor
(vertical arrow, Figure 2A) and the attainment of a 0.24 unit
change in absorbance (horizontal arrow; corresponding to an
approximate half-maximal absorbance change). Approximately
29 nM total mtCsA3 produced 50% inhibition of PT pore
opening, but no detectable inhibition of CyP-A (Figure 2B).
A total mtCsA3 concentration of 200 nM yielded just 17%
inhibition of CyP-A, indicating an extra-mitochondrial free
mtCsA3 concentration of approximately 1.6 nM (calculated from
Ki =8 nM, Table 1), i.e. that nearly all mtCsA3 had been
accumulatedbymitochondria,withnegligibleamountsremaining
outside for inhibition of CyP-A.
In agreement with previous data [21], CsA itself displayed
no selectivity for the PT pore over extra-mitochondrial CyP-
A (Figure 2B); this would be expected as CsA is bound by
CyP-D and CyP-A with similar afﬁnities (Table 1) and, being
electroneutral, would equilibrate to the same free concentrations
on either side of the mitochondrial inner membrane. To compare
selectivities by mtCsA compounds, Table 1 (rightmost column)
gives the CyP-A inhibition at 50% inhibition of the PT. mtCsA-
selectivity for the PT increased with increased binding afﬁnity for
the target CyP-D (mtCsA3>mtCsA1>mtCsA2)
Non-speciﬁc binding of mtCsA compounds in mitochondria
In line with mitochondrial accumulation, considerably less
mtCsA3 than CsA was needed for PT pore inhibition (I50,
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Figure 3 Relationship between the potencies of mtCsA compounds as
inhibitors of CyP-D and the PT
Intra-mitochondrial I50 values (intra-mitochondrial mtCsA concentration) yielding 50%
inhibition of the PT were obtained by correcting the mean I50 values (Table 1) for
extra-mitochondrial mtCsA concentration. The latter was estimated at each I50 value from
the amount of extra-mitochondrial CyP-A and the degree of CyP-A inhibition: from Table 1
(and since membrane-partitioned CsA at the I50 is small; see text) 60% CyP-A inhibition
corresponds to 96pmol of extra-mitochondrial CsA/mg protein (I50 for CsA − I50 for
mtCsA3), which indicates 150pmol of CyP-A/mg of protein (using Ki =4nM); hence, using
respective Ki values, 9% CyP-A inhibition corresponds to 25pmol of extra-mitochondrial
mtCsA1/mgofprotein,and21%CyP-Ainhibitionto88pmolofextra-mitochondrialmtCsA2/mg
protein, yielding intra-mitochondrial I50 values of 328 (mtCsA1) and 682 (mtCsA2) pmol/mg.
These values were not changed signiﬁcantly when calculated from replicate I50 values and
corresponding CyP-A-inhibition values for mtCsA1 and mtCsA2, i.e. intra-mitochondrial I50:
329+ −25 (mtCsA1) and 677+ −6 (mtCsA2) (means+ −S.E.M., n=3).
29 pmol/mg compared with 125 pmol/mg; Table 1). However, in
the same experimental system, more mtCsA1 was required (I50,
353 pmol/mg), despite its being accumulated by mitochondria
[21]. This suggests that the bulk of mitochondrially accumulated
mtCsA1 was bound non-speciﬁcally. This was also the case with
the other alkyl-linked derivative, mtCsA2 (I50, 770 pmol/mg). In
this connection, Scatchard analyses reveal that a small amount of
mitochondrial CsA is partitioned into membrane phospholipids
(approximately 15% at the I50 [27]). The amount of membrane-
partitioned mtCsA would be expected to increase in direct
proportion to the free mtCsA concentration in the mitochondrial
matrix.Inturn,thematrixfreemtCsAconcentrationattheI50 will
increase in proportion to the Ki value of CyP-D for that mtCsA.
This would lead to a linear relationship between the amount
of mitochondrial mtCsA yielding 50% PT inhibition (intra-
mitochondrial I50) and the free mtCsA concentration giving 50%
CyP-D inhibition (Ki for CyP-D). Intra-mitochondrial I50 values
were obtained by correcting the I50 values (which refer to total
mtCsA) for the relatively small amounts of extra-mitochondrial
mtCsA (legend, Figure 3), and these yielded the predicted
linear relationship with Ki (Figure 3). Clearly, differences in
lipid solubility between the mtCsA compounds would produce
deviations from linearity, but any such deviations appear to be
small. It is probable, therefore, that non-selective membrane
binding of the mtCsA compounds was determined largely by the
SMBz-CsAmoietycommontoall,withtheremainingpartsofthe
linkersexertingrelativelylittleinﬂuence.Cationicmitochondrial-
targeting groups, e.g. TPP
+, conjugated to lipophilic molecules
appear to lie on the inner surface of the inner membrane with the
lipophilic moiety in the membrane interior [28].
The ordinate intercept in Figure 3 (at theoretical inﬁnite CyP-D
afﬁnity for mtCsA, when all added mtCsA is bound to CyP-D)
corresponds to the amount of mtCsA bound to CyP-D at the intra-
mitochondrial I50. From this it is clear that, although the fraction
of mitochondrially accumulated mtCsA1 and mtCsA2 actually
bound to CyP-D was relatively small (3 and 1.5% respectively at
the I50) a far greater proportion of mtCsA3 (>50%) was CyP-D-
bound.
Figure 4 Inhibition of reoxygenation-induced necrosis in cardiomyocytes
by CsA and derivatives
Isolated cardiomyocytes were incubated under glucose-free anoxia for 4h and then aerobically
with glucose and 50μM t-butyl hydroperoxide (reoxygenation). When included, CsA and
derivatives were added at the beginning of anoxia. (A–C) Cell necrosis during reoxygenation in
thepresenceandabsenceof50nMCsA,15nMmtCsA3and400nMSMBz–CsA,asindicated,
was determined from nuclear staining with ethidium homodimer. Insets in (A) show cells
dual-stained with Hoechst 33342 (H) and ethidium homodimer (E) after 3 h of reoxygenation.
(DandE)Necrosisafter3hofreoxygenationwiththeindicatedconcentrationsofCsA,mtCsA3
andSMBz–CsA.Resultsaremeans+ −S.E.M.forfourcellpreparations,>200cellscountedper
preparation. *P <0.05 with respect to no addition.
Protection by mtCsA3 in cardiomyocytes
The cytoprotective properties of the improved mtCsA compound
were evaluated in isolated heart cells subjected to simulated I/R
(ischaemia/reperfusion). The cells were ﬁrst exposed to glucose-
free anoxia to mimic ischaemia; in practice, cells could be
maintained under these conditions for approximately 4 h with
little necrosis (<8%). The myocytes were then reoxygenated in
thepresenceofglucoseand50μMt-butylhydroperoxide,andthis
produced progressive cell necrosis amounting to approximately
50% after 5 h (Figures 4A–4C). t-Butyl hydroperoxide was
included to boost oxidative stress, a critical component of RI
[29] and of PT pore opening in cardiomyocytes [1,30]. Other
experiments (results not shown) conﬁrmed that necrosis was
substantially reduced on omission of either t-butyl hydroperoxide
(<15% necrosis after 5 h) or the period of glucose-free anoxia
(no increase in necrosis during 5 h of reoxygenation).
After3 hofreoxygenation,CsAgaveamaximalcytoprotection
of approximately 38% at 50–100 nM (Figure 4D). Increased
CsA concentration to 200 nM decreased cytoprotection and,
in a separate series of paired experiments, 1 μMC s Ag a v e
no protection at all (controls, 25+ −4% necrosis; CsA tests,
25+ −5%; n=4, P= 0.86). This agrees with the reversal
of cytoprotection with increased CsA concentration observed
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previously in isolated adult rat cardiomyocytes [9], isolated
rat hippocampal neurons [21] and perfused rat heart [10]. In
comparison, mtCsA3 delayed the onset of necrosis completely at
3–15 nM (Figure 4E). However, protection was reversed at higher
concentrations and when reoxygenation was prolonged beyond
3 h (Figure 4B).
Theincreasedmaximalcytoprotectiongainedbymitochondrial
targeting most logically reﬂects avoidance of counter-protective
actions of CsA external to mitochondria. These might include
calcineurin inhibition by the CyP–CsA complex and/or inhibition
(PPIase) of CyP-A (cytosol) or other extra-mitochondrial CyPs.
To evaluate the contribution of these factors to the enhanced
protection by mtCsA3, we used SMBz–CsA (compound 2,
Figure1).LikemtCsA3,SMBz–CsAhassimilarbindingafﬁnities
for CyP-D and CyP-A and, in complex with CyP-A, does not
inhibit calcineurin (Table 1). Unlike mtCsA3, however, SMBz–
CsA lacks the mitochondrial-targeting TPP
+ cation and is not
accumulatedbymitochondria,and,beingfreelypermeableacross
themitochondrialinnermembrane,inhibitsbothCyP-DandCyP-
A in cells [21]. Thus the cellular inhibition proﬁle of SMBz–
CsA (inhibiting CyP-D and CyP-A) is distinct from that of CsA
(inhibitingCyP-D,CyP-Aandcalcineurin)andmtCsA(inhibiting
CyP-D) [21]. As shown in Figure 4(D), maximal cytoprotection
by SMBz–CsA (65%) was greater than that given by CsA
(38%), indicating that avoidance of calcineurin inhibition may
contribute to the increased potency of mtCsA3 with respect to
CsA,asshownpreviouslyformtCsA1inneuronalcellsfollowing
glucose-free anoxia [21]. However, maximal protection by the
SMBz–CsA was less than that given by mtCsA3, suggesting that
avoidance of inhibition of CyP-A or other extra-mitochondrial
CyPs also contributes to the enhanced cytoprotection gained by
mitochondrialtargeting.Inthisconnection,bothCyP-AandCyP-
B (sarcoplasmic reticulum) counteract oxidative stress [23,31]
and inhibition of these PPIases may be counter-protective when
oxidative stress is a critical element in the pathogenesis, as in the
present regime.
In conclusion, we have developed a mitochondrial-targeted
CsA with a binding afﬁnity for CyP-D close to that of CsA
itself.Thesetwofeatures,intra-mitochondrialselectivityforCyP-
D and mitochondrial targeting, are designed to minimize non-
CyP-D interactions in cells. In a model system, the mtCsA
counters RI more effectively than CsA, underlining the potential
improvement in cytoprotection to be gained by selective CyP-
D inhibition. MtCsA3 is effective over a discrete concentration
range (Figure 4E) and, to be useful therapeutically, will need to
establish intra-mitochondrial concentrations within the effective
range before PT pore formation takes place. Indications are
that the pore forms quickly on reperfusion. Measurements
in isolated cardiomyocytes of mitochondrial inner membrane
potential [2] and Ca
2+ accumulation capacity [32] reveal that
both are lost within 1–2 min after reoxygenation in non-
recovering cells, consistent with PT pore formation within
this time. Since anti-RI therapeutics can only be delivered
to organs on reperfusion, a key question to be resolved is
whether mtCsA compounds can establish intra-mitochondrial
concentrations within the effective range sufﬁciently quickly,
and whether these concentrations can be maintained within (i.e.
without exceeding) the effective range for a sufﬁcient period of
time. CsA itself seems kinetically adequate in this respect. In
experimental animals, CsA reduces infarct size when introduced
at the time of reperfusion [11]. In patients treated for acute
myocardial infarction, CsA yields some protection against RI
when administered intravenously immediately before coronary
angioplasty [33]. Equally encouraging, conjugation to TPP
+ has
been used to deliver a wide range of lipophilic compounds to
mitochondria in tissues and does so quickly, achieving maximal
levels in the heart within 4 min of intravenous injection and
maintaining these for >1 h [34].
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